RedHill Biopharma
RedHill (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on proprietary drugs for gastrointestinal diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 109 % | (25 %) | 923 % | 33 % | (28 %) | (89 %) | 23 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (463 %) | (646 %) | (85 %) | (73 %) | (56 %) | 196 % | (167 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (464 %) | (672 %) | (118 %) | (114 %) | (116 %) | 366 % | (103 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 297 % | 277 % | 26 % | 34 % | 12 % | 54 % | 20 % |
Source: Company filings or news article
Related Content
RedHill Biopharma is a specialty biopharmaceutical company headquartered in Raleigh, NC, with a strong focus on gastrointestinal (GI) diseases. The company operates primarily in the U.S. market, where it has built a dedicated sales force specializing in GI treatments. RedHill's commercial portfolio includes prescription drugs such as omeprazole, amoxicillin, rifabutin, naloxegol, and rifamycin. These medications are used to treat various GI conditions, making RedHill a key player in this niche market.
RedHill's business model revolves around both the commercialization of existing GI products and the development of new treatments. The company generates revenue by selling its prescription drugs to healthcare providers and pharmacies. Additionally, RedHill is actively involved in drug development, with a pipeline that includes treatments for COVID-19, among other conditions. The company recently received approval for a Phase 2/3 COVID-19 study in Russia, highlighting its commitment to addressing urgent healthcare needs.
RedHill also engages in strategic activities to protect its interests and ensure market integrity. For instance, the company has sought SEC review of suspicious trading activity, demonstrating its vigilance in maintaining a fair trading environment.
In summary, RedHill Biopharma serves healthcare providers and patients in the U.S. GI market through a combination of commercialized products and ongoing drug development. The company makes money by selling its prescription drugs and advancing new treatments through clinical trials.
Keywords: biopharmaceutical, gastrointestinal, prescription drugs, U.S. market, drug development, COVID-19, clinical trials, sales force, healthcare, SEC review.